title: [Tamoxifen or tamoxifen in combination with chemotherapy in adjuvant therapy of breast carcinoma. Results of a multicenter randomized study].
abstract: Between April 1994 and May 1997 103 breast cancer patients (pts), pT1c-3a, pN0-1, M0, were randomised after surgery to adjuvant tamoxifen (20 mg per day) or to tamoxifen plus CMF (C 500 mg/m2, M 40 mg/m2 and F 600 mg/m2 on days 1st and 8th q 28 day) in 6 cycles. The median age (49-72 years, median 58), tumour size, number of involved lymphnodes (0-3), estrogens receptor status, grade (I-III) and type of operation were well balanced among the 50 pts on tamoxifen and the 53 pts on tamoxifen plus CMF pts, preferably postmenopausal.
  
  
  RESULTS
  Grade of toxicity according to WHO criteria was not higher then two in both arms. Toxicity both haematological and non-haematological was higher in the group treated with chemotherapy (0 vs 32 resp. 20%) except weight gain  (52% in both group). After median follow-up of 42 mos five recurrences in tamoxifen and seven in tamoxifen plus CMF pts were observed (p = NS). The projected 3-y DFS is 92% for tamoxifen and 88% for tamoxifen plus CMF (p = NS). The 3-y OS is 88% for tamoxifen and 80% for tamoxifen plus CMF pts (p = NS).
  
  
  CONCLUSIONS
  Both regimens are equally effective with higher toxicity in the group with combined chemo- and hormonal therapy.
authors.affiliation: Onkologická klinika 1: lékarské fakulty Univerzity Karlovy, U nemocnice 2, 128 08 Praha 2, Czech Republic. onkol@lf1.cuni.cz
authors.forename: O
authors.initials: O
authors.lastname: Pribylová
authors.forename: L
authors.initials: L
authors.lastname: Petruzelka
authors.forename: H
authors.initials: H
authors.lastname: Honová
authors.forename: J
authors.initials: J
authors.lastname: Fischer
authors.forename: I
authors.initials: I
authors.lastname: Bustová
authors.forename: H
authors.initials: H
authors.lastname: Siffnerová
authors.forename: M
authors.initials: M
authors.lastname: Kůta
authors.forename: V
authors.initials: V
authors.lastname: Miller
authors.forename: M
authors.initials: M
authors.lastname: Hacklová
authors.forename: J
authors.initials: J
authors.lastname: Machácek
authors.forename: M
authors.initials: M
authors.lastname: Kohoutek
authors.forename: P
authors.initials: P
authors.lastname: Vodvárka
authors.forename: T
authors.initials: T
authors.lastname: Kyselá
authors.forename: J
authors.initials: J
authors.lastname: Tajblová
authors.forename: J
authors.initials: J
authors.lastname: Suk
authors.forename: V
authors.initials: V
authors.lastname: Dorazilová
authors.forename: J
authors.initials: J
authors.lastname: Vedralová
authors.forename: J
authors.initials: J
authors.lastname: Bauer
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D015996:Survival Rate; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen